Literature DB >> 10633228

Increased expression of estrogen receptor beta in human uterine smooth muscle at term.

J J Wu1, E Geimonen, J Andersen.   

Abstract

Expression of the cx43 gene for the gap junction protein, connexin43 (Cx43), through activator protein (AP)-1 activity has been shown to be inhibited in human primary myometrial cultures pretreated with estrogen. In the present study, the primary myometrial cultures were shown to express predominantly ERbeta, a subtype of estrogen receptor that inhibits AP-1 activity when bound to agonists. ERbeta levels were decreased in the primary myometrial cultures after treatment with the phorbol ester, 12-O-tetradecanolyl-13 acetate, to stimulate AP-1 activity, and this effect is inhibited if cells were pretreated with estrogen. Two isoforms of ERbeta were found in primary myometrial and leiomyoma cultured cells. Immunoblot and RT-PCR analyses indicated that ERbeta expression was increased in human term myometrial tissue compared with non-pregnancy tissue. Immunohistochemistry localized ERbeta to the nucleus in cells of term myometrial tissue samples that had high ERbeta expression. ERbeta was increased in term tissue in which Cx43 protein levels were low. In myometrial tissue in which Cx43 protein levels are greatest (e.g. during active labor), ERbeta was barely detectable. Only low levels of ERbeta were detected in non-pregnancy myometrial and leiomyoma tissues, and the lowest levels were found in tissues from mid cycle. In contrast, ERalpha was highly detectable in the non-pregnancy myometrial and leiomyoma tissues, but not in term myometrial tissue samples. This work indicates there is a dramatic switch from ERalpha to ERbeta expression in the myometrium during pregnancy. The results suggest that, during gestation, myometrial ERbeta may inhibit AP-1 activity and thus block induction of the cx43 gene and other labor-associated genes. Labor may ensue after a loss of myometrial ERbeta expression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10633228     DOI: 10.1530/eje.0.1420092

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  7 in total

1.  In vitro responsiveness of human post-menopausal myometrium to endothelin-1 and ovarian steroids.

Authors:  E Domali; P A Molyvdas; I E Messinis
Journal:  J Endocrinol Invest       Date:  2005-06       Impact factor: 4.256

2.  Role of estrogen receptor beta in uterine stroma and epithelium: Insights from estrogen receptor beta-/- mice.

Authors:  Osamu Wada-Hiraike; Haruko Hiraike; Hiroko Okinaga; Otabek Imamov; Rodrigo P A Barros; Andrea Morani; Yoko Omoto; Margaret Warner; Jan-Ake Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-16       Impact factor: 11.205

3.  Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus.

Authors:  Z Weihua; S Saji; S Mäkinen; G Cheng; E V Jensen; M Warner; J A Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

Review 4.  Minireview: regulation of gap junction dynamics by nuclear hormone receptors and their ligands.

Authors:  Gary L Firestone; Bhumika J Kapadia
Journal:  Mol Endocrinol       Date:  2012-08-30

Review 5.  Functional insights into modulation of BKCa channel activity to alter myometrial contractility.

Authors:  Ramón A Lorca; Monali Prabagaran; Sarah K England
Journal:  Front Physiol       Date:  2014-07-31       Impact factor: 4.566

6.  The role of estrogen receptor-beta gene +1730G/A polymorphisms in recurrent pregnancy loss: A protocol for systematic review and meta-analysis.

Authors:  Fangxiang Mu; Minge Shi; Li Huang; Dafen Wang; Aiqun Shen
Journal:  Medicine (Baltimore)       Date:  2021-02-19       Impact factor: 1.817

7.  Beta-Estradiol Regulates Voltage-Gated Calcium Channels and Estrogen Receptors in Telocytes from Human Myometrium.

Authors:  Adela Banciu; Daniel Dumitru Banciu; Cosmin Catalin Mustaciosu; Mihai Radu; Dragos Cretoiu; Junjie Xiao; Sanda Maria Cretoiu; Nicolae Suciu; Beatrice Mihaela Radu
Journal:  Int J Mol Sci       Date:  2018-05-09       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.